Company Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.
The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis.
It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy.
The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure.
NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Apr 4, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 138 |
| CEO | Dr. David J. Woodhouse Ph.D. |
Contact Details
Address: 333 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650-243-5555 |
| Website | ngmbio.com |
Stock Details
| Ticker Symbol | NGM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001426332 |
| CUSIP Number | 62921N105 |
| ISIN Number | US62921N1054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Rieflin J.D. | Executive Chairman of the Board of Directors |
| Dr. David J. Woodhouse Ph.D. | Chief Executive Officer and Director |
| Valerie L. Pierce J.D. | Senior Vice President, General Counsel, Secretary and Chief Compliance Officer |
| Dr. Hsiao Dee Lieu F.A.C.C., M.D. | Chief Medical Officer and Executive Vice President |
| Jean Frederic Viret Ph.D. | Chief Financial Officer |
| Irene Perlich | Vice President, Corporate Controller and Principal Accounting Officer |
| Daniel Kaplan Ph.D. | Chief Scientific Officer |
| Mahi Saraf | Director of People and Culture |
| Diana Peng Bockus | Head of Business Development |
| Arthur Hsu Ph.D. | Senior Director and Head of Biology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 25-NSE | Filing |
| Apr 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 5, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 5, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 5, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 5, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 5, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 5, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 5, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |